Resources
19 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/11/2023 (updated 3/26/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has new resources available when supporting pregnant and parenting people with substance use disorders. Each resource supplements the SAMHSA Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.
Posted 7/20/2022 (updated 3/27/2024)
Researchers looked at survey responses from women of reproductive age across eight rural U.S. regions to determine the association between contraceptive use and SUD treatment, healthcare utilization, and substance use.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 3/7/2023 (updated 3/27/2024)
Although pregnancy is motivation for opioid use disorder treatment, there is a risk of relapsing after childbirth. Unpacking Perinatal Experiences with Opioid Use Disorder: Relapse Risk Implications studies the perinatal experiences that can inform clinical social workers and other health/behavioral health providers on when and how to provide support during this time period.
Posted 12/18/2023 (updated 3/28/2024)
This study looks at perinatal care for pregnant people with substance use disorders. Stigma and lack of access to treatment and recovery increases the risk for pregnant people. Results and suggestions from the study include the need to expand OUD treatment training, clarification on child welfare reporting rules, the need to include philanthropic investment, and more.
Posted 7/17/2020 (updated 3/28/2024)
Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%–22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.
Posted 2/19/2024 (updated 3/28/2024)
The Bureau of Justice Statistics (BJS), in the Department of Justice’s Office of Justice Programs, released Data on Maternal Health and Pregnancy Outcomes from Prisons and Jails: Results from a Feasibility Study. The study examined the availability and quality of data, the respondent burden, and the challenges of collecting data on the health and health care of pregnant women in custody at the federal, state, local and tribal levels. BJS will use the findings of this study to help determine the best strategies for implementing national data collections in correctional settings.
Posted 2/23/2024 (updated 3/28/2024)
Esteemed maternal health professionals in partnership with the de Beaumont Foundation and the MHLIC released The Practical Playbook III: Working Together to Improve Maternal Health. This comprehensive and groundbreaking work serves as a crucial resource for professionals across diverse fields, providing practical and actionable guidance.
Posted 8/24/2020 (updated 3/28/2024)
Medications for opioid use disorder, including buprenorphine hydrochloride and methadone hydrochloride, are highly effective at improving outcomes for individuals with the disorder. For pregnant women, use of these medications also improves pregnancy outcomes, including the risk of preterm birth. Despite the known benefits of medications for opioid use disorder, many pregnant and nonpregnant women with the disorder are not receiving them.